Raloxifene
imparts anticancer benefit
The anti-osteoporosis drug raloxifene
seems to prevent breast cancer in many postmenopausal women worldwide.
References:
Cummings, S.R., et al. 1999. The effect of raloxifene on risk
of breast cancer in postmenopausal women. Journal of the American
Medical Association 281(June 16):2189.
Further Readings:
1998. New estrogen may hold greater appeal. Harvard Health Letter
23(March):7.
Delmas, P.D., et al. 1997. Effects of raloxifene on bone mineral
density, serum cholesterol concentrations, and uterine endometrium
in post-menopausal women. New England Journal of Medicine 337:1641.
Eastell, R. 1998. Treatment of postmenopausal osteoporosis. New
England Journal of Medicine 338(March 12):736.
Franks, A.L., and K.K. Steinberg. 1999. Encouraging news from the
SERM frontier. Journal of the American Medical Association
281(June 16):2243.
Fuleihan, G.E.-H. 1997. Tissue-specific estrogens—the promise
for the future. New England Journal of Medicine 337(Dec. 4):1686.
Khovidhunkit, W., and D.M. Shoback. 1999. Clinical effects of raloxifene
hydrocholoride in women. Annals of Internal Medicine 130:431.
Sources:
Steven R. Cummings
Prevention Sciences Group
74 New Montgomery
Suite 600
San Francisco, CA 94105
Leo Plouffe
Eli Lilly and Co.
Drop Code 4121
Indianapolis, IN 46285
Michael B. Sporn
Dartmouth Medical School
Department of Pharmacology
Hanover, NH 03755
From Science
News, Vol. 155, No. 25, June 19, 1999, p. 388.
Copyright © 1999, Science Service.
